A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recruiting · Phase 3 · NCT06875310
Conditions: Carcinoma, Non-Small-Cell Lung
At a glance
- Research payments reported, 2025
- $6,775
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 630
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- Adagrasib (drug), Pembrolizumab (drug), Carboplatin (drug), Pemetrexed (drug), Placebo (drug), Cisplatin (drug)
- Dates
- Started 2025-04-24; completion 2032-04-30
- Results posted
- Not yet
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $6,775 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Boston Imaging Core Lab Llc $6,775
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.